Clinical trial
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat…
NCT00239447 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00239447 |
|---|---|
| Title | Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD |
| Official title | Efficacy and Safety Comparison of 4-week Treatment Periods of Two Doses [5 μg (2 Actuations of 2.5 μg) and 10 μg (2 Actuations of 5 μg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Tiotropium Inhalation Powder Capsule (18μg) Delivered by the HandiHaler in Patients With… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Device, Drug |
| Interventions | Tiotropium, HandiHaler, Respimat SMI |
| Enrollment | 131 |
| Start date | Nov 26, 2002 |
| Primary completion | Apr 29, 2004 |
| Completion | Apr 29, 2004 |
| First posted | Oct 17, 2005 |
| Last update posted | Dec 1, 2023 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: